Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Stephanie Seremetis"'
Autor:
Bendix Carstensen, Stephen C Bain, Hanan Amadid, Alice Clark, Liselotte Hyveled, Stephanie Seremetis, Frederik Flindt Kreiner
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 11, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/aa780592781249ba85931358967af496
Autor:
Sille Esbjerg, Elina Asikanius, Peter J. Kuebler, Soraya Benchikh El Fegoun, Gallia G. Levy, Stephanie Seremetis
Publikováno v:
Journal of Thrombosis and Haemostasis. 17:1470-1477
Background Recombinant activated factor VII (rFVIIa; eptacog alfa activated, NovoSeven® , Novo Nordisk A/S) is a bypassing agent used in congenital hemophilia A patients with inhibitors. Emicizumab (Hemlibra® ; F Hoffmann-La Roche Ltd) is a recombi
Autor:
Ellis J. Neufeld, Doris Quon, Paul Giangrande, Stephanie Seremetis, C. S. Hoxer, David L. Cooper, Neeraj N. Iyer, Christopher E. Walsh, L. Solimeno
Publikováno v:
Haemophilia. 23:821-831
Background While there is substantial literature addressing the principles of general management of haemophilia, literature on perioperative management of haemostasis is scarce. Objective The aim of this study was to better understand perioperative m
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis. 24:549-559
Agents that control bleeding and the usage of bypassing agents have made surgery an option to consider in people with hemophilia. However, the lack of consistent definitions for major or minor surgery may lead to inconsistencies in patient management
Autor:
David L. Cooper, A. Rojas-Rios, Stephanie Seremetis, Ellis J. Neufeld, Claude Negrier, S. Benchikh el Fegoun
Publikováno v:
Haemophilia. 24:e275-e277
Autor:
S. C Tamer, Jesper Haaning, Josephine Skovgaard Rasmussen, Stephanie Seremetis, Trine Høyer Rose, Thomas Porstmann, Katarina Cepo
Publikováno v:
Blood. 136:40-40
Introduction Concizumab, a humanized recombinant monoclonal antibody directed against the tissue factor pathway inhibitor, is under investigation as a subcutaneous prophylactic treatment for patients with hemophilia A or B (HA/HB) with and without in
Publikováno v:
Clinical Investigation. 5:755-766
Hemophilia A is an X-linked recessive hereditary bleeding disorder resulting from a deficiency in coagulation factor VIII. Difficulties due to hemophilia and its management present challenges for patient's quality of life. Turoctocog alfa, a recombin
Autor:
Soraya Benchikh El Fegoun, Per Arkhammar, Ellis J. Neufeld, Mette Duelund Simonsen, Anders Rosholm, Claude Negrier, Stephanie Seremetis
Publikováno v:
Blood Reviews. 29:S34-S41
This updated safety review summarises the large body of safety data available on the use of recombinant activated factor VII (rFVIIa) in approved indications: haemophilia with inhibitors, congenital factor VII (FVII) deficiency, acquired haemophilia
Autor:
Per Arkhammar, Anders Rosholm, Stephanie Seremetis, Francesco Baudo, Soraya Benchikh El Fegoun, Alice D Ma, Kagehiro Amano, Andreas Tiede
Publikováno v:
Blood Reviews. 29:S19-S25
Acquired haemophilia (AH) is a rare, often severe bleeding disorder characterised by autoantibodies to coagulation factor VIII (FVIII). Observational studies offer crucial insight into the disease and its treatment. Recombinant activated factor VII (
Publikováno v:
Expert Opinion on Orphan Drugs. 2:419-431
Introduction: Prophylactic replacement therapy with factor VIII (FVIII) is recommended as the foundation of treatment for severe hemophilia A; however, access to such therapy remains limited in many parts of the world. Introducing new products into t